莫德纳

最新新闻

• Yunteng Xinyao rose in early trading after the company appointed two Moderna oncology vaccine scientists, accelerating its global mRNA clinical development.
  Zhitong Finance · 2026/10/9
• 评级变动
  US Stock Market Update: Moderna (MRNA.US) Surges Over 10% After Multiple Wall Street Banks Raise Price Targets
  Zhitong Finance · 2026/8/25
• 评级变动
  A Quick Look at Today's Ratings for Moderna(MRNA.US), With a Forecast Between $40 to $170
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 公司公告
  Nano Holdings: Statutory Post-Disclosure Documents (Corporate Split) (NANO MRNA Co., Ltd.)
  JPX · 2026/4/24
• 公司公告
  Nano Holdings: Notice Regarding the Transfer of a Subsidiary Resulting from NANO MRNA, a Strategic Subsidiary, Acquiring Shares in Luna RD Co., Ltd. (Making It a Wholly Owned Subsidiary)
  JPX · 2026/4/24
• 评级变动
  Wolfe Research Upgrades Moderna(MRNA.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  Rothschild & Co Redburn Initiates Moderna(MRNA.US) With Sell Rating, Announces Target Price $81
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 公司公告
  CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - SYS6037 INJECTION (MPOX MRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
  HKEX · 2026/8/10
• Overnight U.S. Stocks | Trump states Russia agrees to supply diesel to alleviate fuel price pressures; three major indices close higher for the week; Moderna (MRNA.US) surges over 14%
  Zhitong Finance · 2026/10/10
• BofA Securities Maintains Moderna(MRNA.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  DBS Maintains Moderna(MRNA.US) With Hold Rating, Raises Target Price to $150
  \u5e02\u573a\u8d44\u8baf · 2026/9/12
• 评级变动
  J.P. Morgan Maintains Moderna(MRNA.US) With Sell Rating, Raises Target Price to $77
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 公司公告
  Nano Holdings: New research findings on mRNA therapeutics have been announced by the group led by Professor Akihisa Iitaka.
  JPX · 2026/9/4
• mRNA cancer vaccines enter the confirmatory validation window; the underlying index of the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) rose nearly 4% today.
  Latest · 2026/9/30
• 评级变动
  Yunteng Xinyao (01952.HK): First-half 2026 results in line with expectations; leading progress in mRNA oncology vaccine development.
  CICC · 2026/8/21
• 评级变动
  Yunteng Xinyao (01952.HK): Its core product, NaiFuKang, continues to see robust volume growth, while its mRNA pipeline is advancing rapidly.
  Essence Securities · 2026/8/24
• 公司公告
  Nano Holdings: (Correction) Regarding a Partial Correction to the "Notice on Changes in Subsidiaries Resulting from Luna RD Co., Ltd.'s Acquisition of Shares in Luna RD Co., Ltd. by Strategic Subsidiary NANO MRNA (Subsidiarization)"
  JPX · 2026/4/24
• With the addition of two former senior oncology vaccine scientists from Moderna, Everest Medicines accelerates its global clinical development of mRNA therapies.
  Gelonghui Finance · 2026/10/9
• 评级变动
  Argus Research Upgrades Moderna(MRNA.US) to Buy Rating, Announces Target Price $180
  \u5e02\u573a\u8d44\u8baf · 2026/8/28
• 评级变动
  J.P. Morgan Maintains Moderna(MRNA.US) With Sell Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• mRNA‑related stocks lead gains: CanSino Biologics tops the pack, while Moderna's mRNA neoantigen therapy is set to debut at the ESMO Congress.
  Zhitong Finance · 2026/9/30
• Hong Kong Stock Market Movers | CSPC Pharma (01093) rises nearly 6% following consecutive announcements of R&D progress, including developments in mRNA cancer vaccines and recombinant protein vaccines.
  Zhitong Finance · 2026/9/30
• CanSino Biologics: Currently developing mRNA-based prophylactic vaccines and therapeutic biologics, as well as related delivery systems.
  Latest · 2026/9/30
• CanSino Biologics: Currently developing mRNA-based preventive vaccines and therapeutic biologics, along with related delivery systems.
  Latest · 2026/9/30
• Form 144 | Moderna(MRNA.US) Officer Proposes to Sell 4.69 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 9/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。